fda announcement tirzepatide Grants a New Indication for Obesity Management New Medication approved by the

This profile makes the peptide attractive for athletes prioritizing recovery without unwanted hormonal side effects

Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, et al

The status of Nrf2 is a key determinant of the effect of System X c GSH/GPX4 axis-targeted therapy in HCC, and therefore it is necessary to improve efficacy by inhibiting Nrf2 expression

doi: 10.1002/jsfa.7503 36

These small changes add up to fewer denials and faster payments

This blog draws from insights shared during our recent webinar on payer perspectives on GLP-1 therapies, using data from our 2025 Trends in Drug Benefit Design Report